Mayday implements single sign-on with smartcard and PIN

详细信息	查看全文 | 推荐本文 |

• 关键词：Titanium dioxide ; Nanoparticles ; UVA ; Oxidative stress ; DNA damage ; ESR
• 刊名：Card Technology Today
• 出版年：2008
• 期刊代码：15_09652590
• 类别：cp
• 出版时间：March 2008
• 卷：20
• 期：3
• 页码：6-7
• 文件大小：75 K

摘要

We analysed postmenopausal women (mean age 64 years [SD 9]) with localised breast cancer randomly assigned to anastrozole (n=3125) or tamoxifen (n=3116). Efficacy measures, including death and risk-benefit indices, were analysed by intention to treat. Safety analyses were based on treatment first received (n=3092 for anastrozole and n=3094 tamoxifen). We calculated a risk-benefit analysis using the two global indices for the Women's Health Initiative and for Disease-Free Survival and Serious Adverse Events. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.

Findings

At median follow-up of 68 months (range 1–93), treatment-related adverse events occurred significantly less often with anastrozole than with tamoxifen (1884 [61%] vs 2117 [68%]; p<0·0001), as did treatment-related serious adverse events (146 [5%] vs 277 [9%]; p<0·0001) and adverse events leading to withdrawal (344 [11%] vs 442 [14%]; p=0·0002). Patients given anastrozole had significantly fewer overall events for the Global Index of the Women's Health Initiative (744 [24%] vs 851 [27%]; hazard ratio 0·85 [95%CI 0·77–0·94], p=0·001) and the Global Index of Disease-Free Survival and Serious Adverse Events (1453 [46%] vs 1594 [51%]; 0·88 [0·82–0·94]; p=0·0004).

Interpretation

Anastrozole is tolerated better than tamoxifen by postmenopausal women with early-stage breast cancer, and results in fewer serious adverse events. Furthermore, it has a more favourable overall risk-benefit profile and lower recurrence rate than tamoxifen.